Discovery of LHRH and development of LHRH analogs for prostate cancer treatment

Prostate. 2017 Jun;77(9):1036-1054. doi: 10.1002/pros.23360. Epub 2017 Apr 27.

Abstract

The discovery, isolation, elucidation of structure, synthesis, and initial testing of the neuropeptide hypothalamic luteinizing hormone-releasing hormone (LHRH), which regulates reproduction, is briefly described. The design, synthesis, and experimental and clinical testing of agonistic analogs of LHRH is extensively reviewed focusing on the development of new methods for the treatment of prostate cancer. Subsequent development of antagonistic analogs of LHRH is then faithfully recounted with special emphasis on therapy of prostate cancer and BPH. The concepts of targeted therapy to peptide receptors on tumors are re-examined and the development of the cytotoxic analogs of LHRH and their status is reviewed. The endeavor to develop better therapies for prostate cancer, based on LHRH analogs, guided much of our work.

Keywords: CRPC; advanced prostate cancer; androgen deprivation therapy; luteinizing hormone-releasing hormone; targeted therapy.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Gonadotropin-Releasing Hormone* / analogs & derivatives
  • Gonadotropin-Releasing Hormone* / metabolism
  • Gonadotropin-Releasing Hormone* / pharmacology
  • Humans
  • Male
  • Medication Therapy Management
  • Molecular Targeted Therapy / methods
  • Neoplasm Staging
  • Prostatic Neoplasms* / drug therapy
  • Prostatic Neoplasms* / pathology
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Gonadotropin-Releasing Hormone